3 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 3 of 3 clinical reviews.
Inclisiran (Leqvio) modestly reduces Lp(a) by 15 to 20% through PCSK9 silencing. Review of ORION trial data, mechanism, monitoring timing, and clinical significance for cardiovascular risk.
Inclisiran (Leqvio) reduces apolipoprotein B (ApoB) by approximately 25-27% in phase 3 ORION trials. Learn the mechanism, magnitude, time course, and monitoring recommendations for ApoB on inclisiran therapy.
Does Leqvio raise or lower ALT? A clinical deep-dive into inclisiran's effect on ALT levels, with RCT data, monitoring guidance, and answers to common patient questions.